VIMTA LABS
|
VIMTA LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| CEPS(Rs) | 33.92 | 35.65 | 29.24 | 20.12 | 12.56 |
| DPS(Rs) | 2.00 | 2.00 | 2.00 | 2.00 | - |
| Book NAV/Share(Rs) | 141.18 | 124.46 | 104.52 | 87.92 | 78.19 |
| Tax Rate(%) | 24.73 | 25.89 | 25.78 | 25.00 | 17.23 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 27.27 | 29.83 | 28.85 | 25.14 | 16.57 |
| EBIT Margin(%) | 17.79 | 21.26 | 20.55 | 14.58 | 6.66 |
| Pre Tax Margin(%) | 17.12 | 20.43 | 20.01 | 13.55 | 4.58 |
| PAT Margin (%) | 12.89 | 15.14 | 14.85 | 10.16 | 3.79 |
| Cash Profit Margin (%) | 23.63 | 24.79 | 23.24 | 21.11 | 15.37 |
| Performance Ratios | |||||
| ROA(%) | 10.93 | 14.53 | 14.29 | 8.25 | 2.79 |
| ROE(%) | 13.94 | 19.02 | 19.43 | 11.66 | 3.96 |
| ROCE(%) | 17.81 | 24.59 | 23.92 | 14.25 | 5.84 |
| Asset Turnover(x) | 0.85 | 0.96 | 0.96 | 0.81 | 0.74 |
| Sales/Fixed Asset(x) | 0.99 | 1.09 | 1.12 | 0.99 | 0.89 |
| Working Capital/Sales(x) | 3.07 | 2.99 | 3.63 | 3.72 | 4.72 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.01 | 0.91 | 0.89 | 1.01 | 1.13 |
| Receivable days | 95.75 | 90.00 | 98.63 | 113.74 | 116.83 |
| Inventory Days | 27.13 | 22.94 | 20.99 | 27.52 | 34.60 |
| Payable days | - | - | - | 1,549.17 | - |
| Valuation Parameters | |||||
| PER(x) | 24.04 | 14.44 | 16.86 | 16.63 | 19.14 |
| PCE(x) | 13.11 | 8.82 | 10.77 | 8.00 | 4.72 |
| Price/Book(x) | 3.15 | 2.52 | 3.01 | 1.83 | 0.76 |
| Yield(%) | 0.45 | 0.64 | 0.63 | 1.24 | - |
| EV/Net Sales(x) | 3.08 | 2.11 | 2.53 | 1.80 | 0.87 |
| EV/Core EBITDA(x) | 10.78 | 6.82 | 8.62 | 7.06 | 4.78 |
| EV/EBIT(x) | 17.30 | 9.91 | 12.32 | 12.36 | 13.09 |
| EV/CE(x) | 2.89 | 2.26 | 2.31 | 1.39 | 0.64 |
| M Cap / Sales | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 0.02 | 14.34 | 32.09 | 16.58 | - |
| Core EBITDA Growth(%) | -7.68 | 20.33 | 51.97 | 63.15 | - |
| EBIT Growth(%) | -16.32 | 18.29 | 86.22 | 155.16 | - |
| PAT Growth(%) | -14.87 | 16.55 | 93.09 | 212.71 | - |
| EPS Growth(%) | -15.02 | 16.45 | 93.09 | 212.71 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.05 | 0.08 | 0.16 | 0.19 |
| Current Ratio(x) | 2.91 | 2.86 | 2.60 | 2.05 | 1.67 |
| Quick Ratio(x) | 2.46 | 2.46 | 2.24 | 1.78 | 1.37 |
| Interest Cover(x) | 26.67 | 25.57 | 38.17 | 14.16 | 3.20 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.03 | 0.09 | 0.25 |
Compare Financial Ratios of peers of VIMTA LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VIMTA LABS | ₹2,064.8 Cr | -0.7% | 25.7% | 111.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,948.0 Cr | -0% | 0.5% | 46.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹157,873.0 Cr | -3% | 0.9% | 61.2% | Stock Analytics | |
| CIPLA | ₹116,809.0 Cr | -2.1% | -6.9% | 19.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,963.0 Cr | -0.6% | -3.3% | 7.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,173.2 Cr | -1.9% | 0.7% | 54.5% | Stock Analytics | |
VIMTA LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VIMTA LABS | -0.7% |
25.7% |
111.2% |
| SENSEX | -0.6% |
2.3% |
16.9% |
You may also like the below Video Courses
